
Episode 49
Biotech Hangout
00:00
Is the Biotech Company Asking Tough Questions?
We hold the external research that we evaluate to the exact same analysis of advancing internal pipelines. There is no difference. Unmet need, tractability, scope of impact of this particular therapeutic lab road,. The breadth of utility, which can be many autoimmune diseases or a single pediatric neurological disease. And then lastly, the business case. By and large, the elite biotechs do a pretty good job on these dimensions.
Transcript
Play full episode